Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berberine for Prevention of Contrast-Induced Acute Kidney Injury
NCT02808351Phase 4Completed
- Sponsor
- Nanjing First Hospital
- Start
- Jul 2016
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of berberine in contrast-induced nephropathy (CIN) (2 arms), sponsored by Nanjing First Hospital. Primary endpoint: Contrast-induced nephropathy at 72 hours. Started Jul 2016; status: completed.
02
Drugs
berberine
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on NCT02808351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02808351.